Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR
SAN DIEGO, May 16, 2011 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC) today announced its participation in the Paris course for Revascularization (EuroPCR) from May 17 – 20. Volcano's focus will be on highlighting the strength of its product portfolio, which includes innovative devices like the Vascular Imaging Balloon Catheter (VIBE® RX), and its sponsorship of a symposium that highlights the use and value of Precision Guided Therapy in clinical practice today.
"Volcano is excited to share our state-of-the-art intravascular therapy guidance and optimization solutions at this year's EuroPCR," commented Scott Huennekens, President and CEO of Volcano. "Globally, clinicians are pleased about the insight our technologies provide them so they can more precisely personalize the treatment of their patients."
Scientific Symposium on Precision Guided Therapy
Volcano is sponsoring a symposium designed to provide real world experiences and novel techniques from key opinion leaders in interventional cardiology from France, Poland, Italy, and the UK. "Precision Guided Therapy: Simple techniques to go beyond angiography in everyday practice" will take place on Wednesday, May 18th, in Room 352AB in the Palais Des Congres.
Volcano will feature its suite of precision guided therapy technologies, which includes integrated cath lab systems, coronary and peripheral IVUS catheters, and physiology guide wires measuring both pressure and flow. These products, which are all available for sale in the U.S. and/or Europe, include:
- The PrimeWire PRESTIGE™, the next generation Fractional Flow Reserve (FFR) wire with a familiar frontline tip, better torque and more support for challenging lesions;
- The Eagle Eye® Platinum, the #1 digital IVUS catheter in
the world, w